Document:

Exhibit 4.11

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

	Item 1.	Name and Address of Reporting Issuer
	 	 
	 	Emerald Health Therapeutics, Inc. (the “Company”)
	 	PO Box 24076, 4420 West Saanich Road
	 	Victoria, British Columbia  V8Z 7E7
	 	 
	Item 2.	Date of Material Change
	 	 
	 	May 15, 2018
	 	 
	Item 3.	News Release
	 	 
	 	A news release was disseminated on May 15, 2018 through GlobeNewswire and subsequently filed on SEDAR.
	 	 
	Item 4.	Summary of Material Changes
	 	 
	 	The Company announced that it entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor agreed to purchase 4,000,000 units of the Company (the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000.  The Investor also agreed to purchase from Emerald Health Sciences Inc. (“Sciences”), a control person of the Company, 2,000,000 common shares held by Sciences at a price of $4.20 per share.
	 	 
	Item 5.	Full Description of Material Change
	 	 
	 	The Company announced that it entered into a binding term sheet with the Investor under which the Investor agreed to purchase 4,000,000 Units at a price of $4.20 per Unit for total gross proceeds of $16,800,000(the “Offering”). The Investor also agreed to purchase from Sciences, a control person of the Company, 2,000,000 common shares held by Sciences at a price of $4.20 per share (the “Secondary Sale”).
	 	 
	 	Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to acquire one common share of the Company (a “Warrant Share”) at a price of $5.20 per Warrant Share for a period of eighteen months following the closing of the Offering, subject to accelerated expiry provisions.
	 	 
	 	The Units and common shares to be sold under the Secondary Sale will be offered by way of a shelf prospectus supplement to be filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 - Short Form Prospectus Distributions.
	 	 
	 	The Company intends to use the net proceeds of the Offering to fund the completion of its recently acquired Agro-Biotech facility in Quebec, working capital, and general corporate purposes.

 

     

     

    

 

	Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102
	 	 
	 	Not applicable.
	 	 
	Item 7.	Omitted Information
	 	 
	 	Not applicable.
	 	 
	Item 8.	Executive Officer
	 	 
	 	For further information, please contact:
	 	Chris Wagner
	 	Chief Executive Officer
	 	Telephone:  1.800.757.3536 ext.720
	 	 
	Item 9.	Date of Report
	 	 
	 	May 15, 2018

 

    	 	- 2 -Exhibit 4.12

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

		Item 1.	Name and Address of Reporting Issuer

 

Emerald Health Therapeutics, Inc. (the “Company”)

PO Box 24076, 4420 West Saanich Road

Victoria, British Columbia V8Z 7E7

 

		Item 2.	Date of Material Change

 

May 22, 2018

 

		Item 3.	News Release

 

A news release was disseminated on
May 23, 2018 through GlobeNewswire and subsequently filed on SEDAR.

 

		Item 4.	Summary of Material Changes

 

The Company announced that, further
to its news release dated May 15, 2018, it closed its prospectus sale (the “Offering”) to a single Canadian institutional
accredited investor (the “Investor”). Pursuant to the Offering, the Investor purchased 4,000,000 units of the Company
(the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000. The Investor also purchased from
Emerald Health Sciences Inc. (“Sciences”), a control person of the Company, 2,000,000 common shares held by Sciences
at a price of $4.20 per share.

 

		Item 5.	Full Description of Material Change

 

The Company announced it had closed
the Offering to the Investor. Pursuant to the Offering, the Company issued 4,000,000 Units at a price per Unit of $4.20 for gross
proceeds of $16,800,000.

 

Each Unit consists of one common
share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to
acquire one common share of the Company (a “Warrant Share”) at a price of $5.20 per Warrant Share for a period of eighteen
months following the closing of the Offering. In the event that the closing sale price of the Company’s common shares (the
“Common Shares”) on the TSX Venture Exchange or such other principal stock exchange on which the Common Shares are
then listed is greater than $6.50 per Common Share for a period of twenty consecutive trading days at any time after the closing
of the Offering, the Company may accelerate the expiry date of the Warrants by giving notice to the Investor and in such case the
Warrants will expire on the 30th day after the date on which such notice is given by the Company.

 

The Units were offered by way of
a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 -
Short Form Prospectus Distributions.

 

     

     

    

 

The Company intends to use the net
proceeds of the Offering to fund the completion of its recently acquired Agro-Biotech facility in Quebec, for working capital,
and for general corporate purposes.

 

The previously announced purchase
by the Investor of 2,000,000 Common Shares from Sciences, a control person of the Company, at a price of $4.20 per share, has also
closed.

 

		Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

		Item 7.	Omitted Information

 

Not applicable.

 

		Item 8.	Executive Officer

 

For further information, please contact:

Chris Wagner

Chief Executive Officer

Telephone: 1.800.757.3536 ext.720

 

		Item 9.	Date of Report

 

May 31, 2018

 

    	 	- 2 -Exhibit 4.13

 

Form 51-102F3

MATERIAL CHANGE REPORT

 

		Item 1.	Name and Address of Reporting Issuer

 

Emerald Health Therapeutics, Inc. (the “Company”)

PO Box 24076, 4420 West Saanich Road

Victoria, British Columbia V8Z 7E7

 

		Item 2.	Date of Material Change

 

September 26, 2018

 

		Item 3.	News Release

 

A news release was disseminated on
September 26, 2018 through GlobeNewswire and subsequently filed on SEDAR.

 

		Item 4.	Summary of Material Changes

 

On September 26, 2018, the Company
entered into a long term supply agreement (the “Agreement”) with Emerald Health Hemp Inc. (“EHH”)
to purchase CBD-containing hemp biomass for extraction into CBD oil. EHH has rights to production from approximately 500 acres
planted to hemp in Manitoba and Prince Edward Island in 2018, with a plan to expand field operations in 2019. Under the Agreement,
the Company will purchase the entire production of harvested hemp chaff, plant material consisting mainly of flower and leaf, from
the property in 2018 and will purchase the entire production from an expanded area of approximately 1,000 acres in 2019 to 2022,
with an option to renew for an additional two-year period. The hemp chaff is expected to be processed via the Company’s exclusive
alliance with Factors R&D Technologies Ltd., a division of Factors Group of Nutritional Companies Inc., which has extensive
extraction experience and large capacity.

 

EHH is a wholly owned subsidiary
of Emerald Health Sciences Inc. ("EHS"), which also owns approximately 32% of the issued and outstanding shares
of the Company. Accordingly, both EHH and EHS are related parties of the Company for purposes of National Instrument 61-101: Protection
of Minority Security Holders in Special Transactions ("NI 61-101") and the transaction is a related party transaction.
The transaction is exempt from the valuation and minority approval requirements of NI 61-101 pursuant to the exemptions in Sections
5.5(d) and 5.7(c) of NI 61-101.

 

     

     

    

 

		Item 5.	Full Description of Material Change

 

On September 26, 2018, the Company
entered into the Agreement with EHH to purchase CBD-containing hemp biomass for extraction into CBD oil. EHH has rights to production
from approximately 500 acres planted to hemp in Manitoba and Prince Edward Island in 2018, with a plan to expand field operations
in 2019. Under the Agreement, the Company will purchase the entire production of harvested hemp chaff, plant material consisting
mainly of flower and leaf, from the property in 2018 and will purchase the entire production from an expanded area of approximately
1,000 acres in 2019 to 2022, with an option to renew for an additional two-year period. The purchase price for hemp will be set
for each year during the term of the Agreement by an independent third party based on market prices. The Company has the right
to terminate the Agreement prior to the end of the term in certain circumstances on 12 months’ prior notice. The hemp chaff
is expected to be processed via the Company's exclusive alliance with Factors R&D Technologies Ltd., a division of Factors
Group of Nutritional Companies Inc., which has extensive extraction experience and large capacity.

 

In conjunction with Bill C-45, Health
Canada recently issued an exemption to holders of Industrial Hemp licenses to begin collecting, drying, storing and transporting
the chaff of hemp. After October 17, farmers will be able to sell hemp chaff to licensed processors under Bill C-45.

 

The Company is finalizing the terms
of an exclusive arrangement with Factors R&D Technologies Ltd. to initially provide the Company with access to a facility with
operating extraction infrastructure capable of processing up to 1 million kg of biomass and producing up to 600 million softgel
capsules annually. Apart from providing pharmaceutical-grade, industrial-scale manufacturing and expertise, the plan for this collaboration
is to also leverage the Factors Group’s decades of experience in product development, formulation and innovation.

 

EHH is a wholly owned subsidiary
of EHS, which also owns approximately 32% of the issued and outstanding shares of the Company. Accordingly, both EHH and EHS are
related parties of the Company for purposes of NI 61-101 and the transaction is a related party transaction. The transaction is
exempt from the valuation and minority approval requirements of NI 61-101 pursuant to the exemptions in Sections 5.5(d) and 5.7(c)
of NI 61-101.

 

The purpose of the transaction is
to secure significant low-cost cannabinoid supply to serve the Company’s manufacturing and marketing goals. The Company expects
hemp to become the Company's lowest cost source of CBD. The transaction is also expected to expand the Company’s ability
to produce CBD products.

 

Dr. Avtar Dhillon and Messrs. Jim
Heppell and Punit Dhillon, each of whom is a director of the Company, is also a director and/or officer of Emerald Health Sciences
Inc. and/or EHH. Accordingly, each such person has a “disclosable interest” in the transaction under applicable corporate
law. In accordance with applicable corporate law, each such person declared his interest to the Company and abstained from voting
on any resolution of the board of directors of the Company with respect to the transaction. The transaction was negotiated on behalf
of the Company by Mr. Chris Wagner, CEO and a director of the Company. The transaction was approved by unanimous vote of the independent
directors of the Company consisting of Mr. Wagner and Mr. Bob Rai at a meeting of the Company’s board on September 25, 2018.

 

No formal valuation was required
or obtained in connection with the transaction and the Company has not obtained any prior valuations in connection with the subject
matter.

 

    	 	- 2 -	 

     

    

 

Sales of hemp under the Agreement
can commence October 17, 2018. The press release covering the transaction was disseminated 21 days before the effective date of
the Agreement. This material change report is being filed less than 21 days before such date because the date on which the new
Cannabis Act will come into force permitting legalized sales of cannabis in Canada.

 

		Item 6.	Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

		Item 7.	Omitted Information

 

Not applicable.

 

		Item 8.	Executive Officer

 

For further information, please contact:

Rob Hill

Chief Financial Officer

Telephone: 1.800.757.3536 ext. #5

 

		Item 9.	Date of Report

 

October 3, 2018

 

    	 	- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]